Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/science.269.5230.1510 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contributions by Christa Critchley to photosynthesis research and to plant ecophysiology.
Photosynthetica
January 2024
Department of Plant Biology, Department of Biochemistry, and Center of Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Christa Critchley is a distinguished researcher in basic and applied photosynthesis research. Her research has centered on the structure and function of chloroplasts and the application of chlorophyll fluorescence to understanding the way PSII works. In her research, she used two biophysical tools, Nuclear Magnetic Resonance (NMR) and Chlorophyll (Chl) fluorescence, as well as several other biochemical and plant physiological methods.
View Article and Find Full Text PDFPerformance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis.
RMD Open
November 2024
Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Objective: Systemic sclerosis Impact of Disease (ScleroID) is the first comprehensive patient-reported outcome measure (PROM) specifically developed for systemic sclerosis (SSc). We investigated the performance of ScleroID in patients with diffuse cutaneous SSc (dcSSc), as a prerequisite for its use in randomised controlled trials (RCTs) testing potentially disease-modifying drugs.
Methods: All patients with dcSSc from the large, multicentric, ScleroID cohort were included.
Predictive gene expression signature diagnoses neonatal sepsis before clinical presentation.
EBioMedicine
December 2024
Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada. Electronic address:
Article Synopsis
- Neonatal sepsis is a serious condition with vague symptoms, making early diagnosis challenging; researchers aimed to identify gene expression biomarkers at birth to improve early detection.
- In a study of 720 healthy full-term newborns, they compared gene expression data from those later hospitalized for early-onset sepsis (EOS) and others who remained healthy, identifying significant genetic differences.
- A 4-gene signature (HSPH1, BORA, NCAPG2, PRIM1) was developed, showing high predictive accuracy for EOS at birth, indicating that even healthy-appearing infants may already exhibit signs of future sepsis through gene expression changes.
Challenges and Alternatives to Evaluation Methods and Regulation Approaches for Medical Apps as Mobile Medical Devices: International and Multidisciplinary Focus Group Discussion.
J Med Internet Res
September 2024
Leibniz ScienceCampus Digital Public Health, Bremen, Germany.
Article Synopsis
- The rapid growth of medical apps has changed how health care is delivered, allowing easy access to personalized health data for patients and providers, but effectiveness and safety concerns have emerged, challenging the reliance on randomized controlled trials (RCTs) for evaluation and regulation.
- This study explores alternative evaluation methods beyond RCTs for medical apps by analyzing insights from a focus group of public health experts and assessing current regulations in Italy, Germany, Canada, and Australia.
- Findings highlight the limitations of RCTs in evaluating digital health interventions and suggest that there are potentially more effective approaches for ensuring the quality and safety of medical apps.
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France.
Pharmacoecon Open
September 2024
Health Economics & Outcomes Research, Public Health Expertise, 75004, Paris, France.
Introduction: Esophageal and gastroesophageal junction cancer (EC/GEJC) is a poor prognosis disease with a high risk of recurrence even in patients curatively resected. Adjuvant nivolumab is currently used for patients with completely resected (R0) EC/GEJC who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. This study aimed to determine the cost effectiveness of nivolumab in this indication in France according to the collective perspective excluding indirect costs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!